STEREOTACTIC BODY RADIOTHERAPY (SBRT): CHANGING TRENDS IN THE MANAGEMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
Copyright (c) 2019 VIRENDER SUHAG, PROF SUNITA BS, PANKAJ VATS, TEJAS PANDYA, NISHANT LOHIA, VK SINGH, MANU TIWARI
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatocellular carcinoma (HCC) is considered as an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location or due to underlying poor liver function because HCC almost always develop in chronically inflamed livers. Depending on the extent of disease and comorbidities, multiple liver-directed therapy (LDT) options exist for the treatment of HCC. Historically, the use of external-beam radiotherapy (EBRT) for HCC been limited by toxicity to the uninvolved liver and surrounding structures. Advances in RT have improved dose conformality to the tumor and facilitated dose escalation, a key contributor to improved HCC radiation treatment outcomes. These advancements in radiation oncology have led to the emergence of stereotactic body radiation therapy (SBRT) as a promising LDT, which delivers high doses of radiation with a steep dose gradient to maximize local tumor control and minimize radiation-induced treatment toxicity. This review will enlighten the primary physicians and oncology care providers about the promising and evolving role of RT in various stages of HCC.